Change towards innovation
Cancer caused 43.8 million illness throughout the world and had burdened USD 1.16 trillion according to 2018 World Cancer Report, published by International Agency for Research on Cancer (IARC) of WHO. The prevalence rate is estimated to spike when people who have a cancer but not being diagnosed are included. Cancer has been prevalent nowadays and yet the disease still comes with fear and anxiety. To fight against cancer and get back to daily lives, “Quality healthcare service” is essential. But what if your’re not within the reach of skilled healthcare providers, up-to-date medical equipment and adequate medical insurance fund? The results speak for themselves.
BBB wanted to make a breakthrough. As a healthcare technology startup, we set a clear goal of launching a blood testing product which does not require high-end infrastructure to offer “Quality healthcare service.” Keeping this well-defined yet challenging ambition in mind, BBB took the first step towards developing MARK-B. MARK-B should be more of a good testing product. A quality blood tester is all about “accuracy”. MARK-B reads blood proteins in an “easy, quick and accurate” manner. EASY, QUICK and ACCURATE ― these three keywords are feasible thanks to unique electrochemical immunoassay method. The sophisticated method presents accuracy equivalent to lab quality in a handy device, by selecting proteins with antibodies and analyzing electrochemical signal to draw quantitative results. Accurate content of a certain protein not only allows detecting early stage cancer but also monitoring patients under treatment. Presenting lab quality service outside the lab ― the innovative experience for both healthcare professionals and patients.
Another key technology behind MARK-B’s accurate diagnosis is non-powered automatic plasma separation. The tester automatically segregates pure (100%) plasma from traces of whole blood less than a single minute. It doesn’t need centrifugation before the test, optical elements or devices. That’s how BBB succeed in making more reliable and durable blood tester, MARK-B. BBB’s challenge is to pave the way for novel healthcare services through innovative technology. Change towards innovationᅳ that’s the core value of MARK B™ and BBB. - BBB inc. CEO& Founder Jaekyu Choi
Our History
2019. 03 Completed a Joint “Cancer Diagnostic Performance Verification Clinical Trial” with Seoul National University Bundang Hospital
2018. 10 Raised 16.5 million in Series B
2018. 07 Presented MARK-B Technology at American Association for Clinical Chemistry (AACC) in Chicago, USA
2018. 03 ‘MARK-B cancer’ Clinical testing and joint research with Seoul National University Bundang Hospital
2017. 11 Launched elemark® dual check in Korea
2017. 08 Signed OEM contract with GenBody Inc. for supply of rapid test readers for arboviruses and drugs of abuse
2017. 06 Signed MOU with Korea University Guro Hospital to develop next-generation immunodiagnostic kit for cancer, myocardial infarction, and chronic disease
2017. 06 Signed MOU with Busan University to commercialize medical research and infrastructure
2017. 04 Signed OEM contract with Philosys Inc. for supply of glucometers for hospital use
2016. 08 Raised $5 million in Series A round
2015. 10 Winner of Zhongguancun Innoway “2015 Demo The World” in Smart Hardware Sector
2015. 05 Tech-In-Asia Award Winner @beGlobal Seoul 2015
2015. 04 Signed OEM contract with GreenCross MS for supply of in-vitro diagnostic devices for hospitals
2015. 01 Joined HAX Batch 6 program (HAX, Hardware startup accelerator based in Silicon Valley and Shenzhen)
2014. 10 Founded headquarters in Korea
Products
Resent Publications
Corporate Information
DAECHI CENTER - BUSINESS OFFICE
14F, 26, Samseong-ro 85-gil, Gangnam-gu, Seoul, Republic of Korea
+82-2-565-9653
biz@bbbtech.com [Sales Team]
contact@bbbtech.com [Any other Question]
SAMSUNG CENTER - R&D
7F, 22, Teheran-ro 81-gil, Gangnam-gu, Seoul, Republic of Korea
YATAP CENTER - MAIN OFFICE
28, Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea